---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273272"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:30:46.755102+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q3 2025 R&D expenses $39.8M; rese-cel BLA submission targeted for 2027

## Summary
- R&D expenses of $39.8M in Q3 2025, up from $26.3M a year ago; cash $159.9M as of Sep 30, 2025.
- Myositis registrational cohort (14 patients) set to begin enrollment by year-end 2025; BLA submission planned for 2027.
- FDA alignment on registrational cohort designs for SSc and SLE trials expected by year-end 2025.
- EMA granted PRIME designation for rese-cel in myositis; FDA granted RMAT for SLE/LN and Fast Track for gMG.
- Steve Gavel appointed Chief Commercial Officer; led CARVYKTI launch at Legend Biotech.

## SEC filing metadata
- accession: 0001193125-25-273272
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312525273272/0001193125-25-273272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312525273272/caba-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273272
- JSON: https://secwatch.observer/filing/0001193125-25-273272.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.